About Empros Pharma

Empros Pharma AB was founded in late 2013 by senior researchers and entrepreneurs at Uppsala University together with the external investor Flerie Invest. In 2020 the Board of Directors was strengthened by new members but the guiding principle remains unchanged; to keep full focus on the obesity drug development project and all recourses are put into the progress of the project. Therefore, the organisation is kept as small as possible.

Most other services are procured from consultants and service providers. The model (an almost virtual drug development company) makes Empros Pharma an extremely agile and focused company and all investments go directly into the progress of the drug development project.




Arvid Söderhäll was headhunted as project manager in 2013. During the first year 2014, the main focus was to establish a base of strong intellectual properties and a solid company structure. The company long-term strategies were developed in this phase (regulatory, clinical, IPR and business strategies). The first scientific advice was held at the Swedish Medicinal Products Agency (MPA) in 2014.


In 2015 development of the pharmaceutical formulation of EMP16 was in focus in parallel with continued IPR work. Empros was in the fortunate situation that pharmaceutical development was made in parallel with intellectual properties development. Hence, the advanced formulation of EMP16 is protected by a strong intellectual property.


Already during 2016 Empros Pharma entered the clinical phase by starting the first phase 2a clinical trial. We are very proud over this achievement; from foundation of a company to clinical phase in only two-and-a-half years, and with a very complex pharmaceutical formulation innovation. A second financing round was also closed during 2016.


In 2017 the first clinical trial was reported with positive results. 


During 2018 Empros had full focus on regulatory development resulting in Scientific Advices from regulatory bodies in Sweden, Europe and Korea.


Empros closed a fully financed private equity emission on 2019 opening the possibility to conduct the phase 2a proof-of-concept trial.


Empros is an excellent example of the vibrant life science sector in the Stockholm-Uppsala region where cutting edge knowledge meets capital